NCT02465268View on ClinicalTrials.gov

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

August 9, 2016

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Glioblastoma MultiformeGlioblastomaMalignant GliomaAstrocytoma, Grade IVGBM
Interventions
BIOLOGICAL

pp65-shLAMP DC with GM-CSF

BIOLOGICAL

unpulsed PBMC and saline

DRUG

Td

All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.

DRUG

Saline

BIOLOGICAL

pp65-flLAMP DC with GM-CSF

Trial Locations (3)

27710

Duke University Medical Center, Durham

32610

University of Florida, Gainesville

32806

Orlando Health, Orlando

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Florida

OTHER

NCT02465268 - Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter